Trial Search Results
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.
Stanford is currently not accepting patients for this trial.
- Drug: SAR302503 (TG101348)
Phase 1/Phase 2
- Completion of MF-TG101348-001 study
- Diagnosis of myelofibrosis
- At least 18 years of age
- Any acute or chronic medical abnormality that may increase the risk associated with
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study